Entera Bio (ENTX) Other financing activities (2024 - 2025)

Entera Bio (ENTX) recorded quarterly Other financing activities of $1000.0 in Q3 2025, down 98.67% on a QoQ basis from $75000.0 in Q2 2025.

Entera Bio (ENTX) Other financing activities (2024 - 2025) Analysis & Trends

Entera Bio has disclosed Other financing activities across 2 years of filings, most recently posting $1000.0 for Q3 2025.

Quarterly Other financing activities changed N/A year-over-year to $1000.0 in Q3 2025, while the trailing twelve-month figure through Mar 2026 was $76000.0 (down 85.07% YoY) and the FY2025 annual result came in at $262000.0, down 18.89% from the prior year.
Other financing activities fell to $1000.0 in Q3 2025, from $75000.0 in the prior quarter.
Over five years, Other financing activities peaked at $304000.0 in Q4 2024 and troughed at $1000.0 in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	788,338.31 Bn	788,338.28 Bn	-
2	Belite Bio	56,560.00 Bn	56,560.00 Bn	-
3	Quantum Biopharma	17,329.30 Bn	17,329.30 Bn	-
4	Legend Biotech	3,341.00 Bn	3,340.71 Bn	242.10 Mn
5	Akari Therapeutics	1,727.91 Bn	1,727.91 Bn	-
6	Evaxion A	1,536.68 Bn	1,536.67 Bn	-
7	Psyence Biomedical	238.34 Bn	238.33 Bn	-
8	Vertex Pharmaceuticals	113.42 Bn	106.17 Bn	2.59 Bn
9	Abivax	95.45 Bn	95.45 Bn	-
10	Entera Bio	57.79 Mn	53.65 Mn	-

Download Data